EOLS vs. TNGX, PLRX, ZNTL, ALXO, LBPH, ETNB, PRAX, SAGE, OPK, and ARQT Should you be buying Evolus stock or one of its competitors? The main competitors of Evolus include Tango Therapeutics (TNGX), Pliant Therapeutics (PLRX), Zentalis Pharmaceuticals (ZNTL), ALX Oncology (ALXO), Longboard Pharmaceuticals (LBPH), 89bio (ETNB), Praxis Precision Medicines (PRAX), Sage Therapeutics (SAGE), OPKO Health (OPK), and Arcutis Biotherapeutics (ARQT). These companies are all part of the "pharmaceutical preparations" industry.
Tango Therapeutics (NASDAQ:TNGX ) and Evolus (NASDAQ:EOLS ) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations, dividends and community ranking.
In the previous week, Evolus had 2 more articles in the media than Tango Therapeutics. MarketBeat recorded 12 mentions for Evolus and 10 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.47 beat Evolus' score of -0.36 indicating that Evolus is being referred to more favorably in the news media.
79.0% of Tango Therapeutics shares are held by institutional investors. Comparatively, 90.7% of Evolus shares are held by institutional investors. 6.2% of Tango Therapeutics shares are held by insiders. Comparatively, 5.4% of Evolus shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Evolus received 328 more outperform votes than Tango Therapeutics when rated by MarketBeat users. Likewise, 71.94% of users gave Evolus an outperform vote while only 56.52% of users gave Tango Therapeutics an outperform vote.
Evolus has higher revenue and earnings than Tango Therapeutics. Evolus is trading at a lower price-to-earnings ratio than Tango Therapeutics, indicating that it is currently the more affordable of the two stocks.
Evolus has a net margin of -27.31% compared to Evolus' net margin of -299.88%. Tango Therapeutics' return on equity of 0.00% beat Evolus' return on equity.
Tango Therapeutics has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500. Comparatively, Evolus has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500.
Tango Therapeutics presently has a consensus target price of $17.25, indicating a potential upside of 129.39%. Evolus has a consensus target price of $20.60, indicating a potential upside of 51.58%. Given Evolus' higher probable upside, research analysts plainly believe Tango Therapeutics is more favorable than Evolus.
Summary Evolus beats Tango Therapeutics on 11 of the 17 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding EOLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools
